wafaeman

Wells Fargo Gains on Better-Than-Expected Net Interest Margin; Eli Lilly Gets Berenberg Upgrade
Two major U.S. companies drew investor attention this week for different reasons. Wells Fargo (WFC) benefited from a more encouraging outlook for net interest margin and loan growth, while Eli Lilly (LLY) received a bullish upgrade from Berenberg, highlighting the pharmaceutical giant’s growth prospects beyond its highly successful weight-loss medicines.
Wells Fargo: Improving Net Interest Margin Outlook
Wells Fargo shares gained after CFO Mike Santomassimo indicated that the bank expects third-quarter net interest margin to come in better than previously anticipated. The comments came during the Barclays Global Financial Services Conference and provided investors with a more constructive view of the bank’s underlying lending business.
Net interest margin is an important profitability measure for banks because it reflects the difference between the interest a bank earns from loans and securities and the interest it pays to depositors and other funding sources.
A stronger-than-expected NIM can therefore be a positive signal for Wells Fargo because it suggests the bank may be able to generate more income from its balance sheet.
The bank also maintained its expectation for approximately $50 billion in full-year net interest income, while expenses are projected at around $55.7 billion. Management additionally expects average loan growth to exceed its previous mid-single-digit outlook.
Loan Growth Adds to the Positive Picture
Wells Fargo's management pointed to healthy consumer spending and relatively stable credit conditions in the U.S. as factors supporting its outlook. The bank said there are currently no significant signs of rising loan delinquencies, suggesting that consumer credit remains relatively resilient.
The bank is also continuing to invest in areas such as healthcare, technology, media and telecommunications. Wells Fargo expects investment-banking fees and markets revenue to grow at mid-single-digit rates during the third quarter, according to management commentary.
For investors, the combination of stronger loan growth, stable credit quality and an improved NIM outlook could provide a supportive backdrop for Wells Fargo's earnings.
Eli Lilly Receives a Bullish Berenberg Upgrade
Meanwhile, Eli Lilly received an important boost from Berenberg analyst Kerry Holford, who upgraded the stock from Hold to Buy and increased the price target from $1,220 to $1,400.
The upgrade reflects growing confidence in Lilly's ability to outperform its ambitious 2026 revenue guidance of $85 billion to $87 billion.
Eli Lilly has become closely associated with its blockbuster GLP-1 medicines, including Mounjaro and Zepbound, which have transformed the company's growth profile. However, Berenberg's bullish view emphasizes that Lilly's investment case extends beyond its current obesity-drug franchise.
Pipeline Could Drive the Next Phase of Growth
One of the key factors behind the upgrade is Lilly's broader drug-development pipeline. Berenberg sees potential from upcoming clinical data for retatrutide and combination treatments involving tirzepatide.
The company is also investing heavily in areas beyond obesity and diabetes, including immunology, vaccines and CAR-T therapies. This diversification could help Lilly maintain a strong growth profile even as investor expectations surrounding its GLP-1 business become increasingly demanding.
The upgrade is particularly notable because Berenberg had previously maintained a more cautious stance. The move to Buy suggests the analyst now believes Lilly's pipeline and earnings potential justify a higher valuation.
What Investors Should Watch
For Wells Fargo, investors will likely focus on upcoming quarterly results, net interest income, loan growth, deposit costs and credit quality. A sustained improvement in NIM could strengthen the bank's earnings outlook, although interest-rate movements and funding costs remain important variables.
For Eli Lilly, the major focus will remain on demand for its obesity and diabetes treatments, upcoming clinical-trial results and the company's ability to expand its pipeline.
Bottom Line
Wells Fargo's improved net interest margin outlook provides a positive signal for the banking sector, particularly as investors look for evidence of stronger lending activity and resilient consumers. Meanwhile, Eli Lilly's Berenberg upgrade highlights the possibility that its long-term growth story could be broader than its current GLP-1 dominance.
Both developments show why investors are watching earnings quality, future growth and company pipelines rather than focusing solely on short-term share-price movements. As always, analyst upgrades and management forecasts are not guarantees of future performance, and investors should consider valuation, risks and their own research before making investment decisions.